Donor Government Funding for Family Planning in 2023

This report provides an analysis of donor government funding to address family planning in low- and middle-income countries in 2023, which totaled US$1.47 billion, and was an increase of 7% (US$101 million) compared to the 2022 amount (US$1.37 billion); although, it was still below the peak level reached in 2019 (US$1.58 billion). The overall increase…

Read More

Donor Government Funding for Family Planning Reports

These reports track funding levels of the donor governments that collectively provide the bulk of international assistance for family planning activities and is part of an effort by KFF that began after the London Summit on Family Planning in 2012. It presents their bilateral assistance to low- and middle-income countries as well as contributions to…

Read More

Faltan iniciativas de gobiernos rurales para comunicarse con los residentes que no dominan el inglés

Eloisa Mendoza ha pasado 18 años ayudando a personas que no dominan el inglés a comprender documentos legales complejos. Los guía en medio de eventos estresantes, repletos de denso papeleo, como solicitudes de ciudadanía, divorcios y traducciones de actas de nacimiento. Mendoza trabaja en Elko, Nevada, una región remota en el noreste del estado. Su…

Read More

A Health Economist to lead the NIH

By SAURABH JHA Early on in the COVID-19 pandemic a seroprevalence study from Santa Clara indicated that the viral spread was far greater than was believed. The study suggested that the infection fatality rate (IFR) was much lower than the case fatality rate and perhaps even lower than the suspected IFR. The researchers estimated that…

Read More

How many patients are switching to biosimilars?

That is a key question if long-run drug prices are going to come down for biologic products. We can decompose this question into 3 sub-questions: What share patients initiating therapy start on a biosimilar?What share of patients already using a biologic products switch to a biosimilar?Do patient of physician factors drive biosimilar prescribing patterns? A…

Read More